CA
NZ
UK
AU
IND
US
Jack A. Khattar, Chief Executive Officer and Director of Supernus, Inc., filed a Form 3 initial statement of beneficial ownership on November 4, 2026, disclosing no securities of the issuer held as of the event date of November 2, 2026.
Bethany Sensenig, a newly added director at Supernus, Inc., filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 4, 2026, disclosing no beneficial ownership of company securities as of the November 2, 2026 triggering event.
Director Georges Gemayel filed an initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing no securities of Supernus, Inc. held as of the date he became subject to reporting obligations.
Anthony R. Norwood, Executive Vice President and Chief Human Resources Officer of Saia Inc, filed a Form 4 on November 4, 2026, disclosing a share withholding transaction and a stock option grant dated November 2, 2026.
Kelly W. Benton, VP and Chief Accounting Officer of Saia Inc, filed a Form 4 on November 4, 2026, disclosing a share withholding transaction on November 2, 2026, related to the vesting of restricted shares originally awarded in November 2022.
An amended beneficial ownership statement covering a transaction dated October 28, 2026 was filed on November 4, 2026, by Soumen Das, MiteshKumar Patel, SPACCatalyst LLC, and SPACCircle Sponsor LLC, each identified as reporting persons with respect to SPACCircle Acquisition Corp. (NASDAQ:SCQCU).
A Statement of Changes in Beneficial Ownership was filed on November 4, 2026, disclosing that SPACCircle Sponsor LLC surrendered 750,000 Class B ordinary shares of SPACCircle Acquisition Corp. to the issuer for no consideration, following the underwriters' forfeiture of the over-allotment option in connection …
Director Todd C. Fowler filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 4, 2026, disclosing his initial beneficial ownership position in Saia Inc following an event date of October 29, 2026.
Director Fred Hassan filed a Form 4 with the SEC on November 4, 2026, disclosing the acquisition of 156,658 restricted stock units in Recursion Pharmaceuticals, Inc. on November 2, 2026.
Director Blake Borgeson of Recursion Pharmaceuticals, Inc. filed a Form 4 on November 4, 2026, disclosing the sale of 40,000 shares of Class A Common Stock on November 3, 2026, under a pre-established Rule 10b5-1 trading plan.
Please wait processing your request...